Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on developing novel therapies for cancer, with a strong emphasis on acute myeloid leukemia (AML) and other hematologic malignancies. This news page aggregates company announcements, clinical updates, financial disclosures, and collaboration news related to SLS.
Readers can follow developments around SELLAS’ lead product candidate galinpepimut-S (GPS), a WT1-targeted peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center, which is being evaluated in the pivotal Phase 3 REGAL trial as a potential maintenance therapy in AML after second complete remission. News items include updates on the REGAL trial’s progress, Independent Data Monitoring Committee recommendations, and commentary from investigators and key opinion leaders.
The SLS news feed also covers SLS009 (tambiciclib), SELLAS’ highly selective CDK9 inhibitor. Articles highlight Phase 2 clinical data in relapsed or refractory AML with myelodysplastic syndrome-related changes (AML-MR) after prior venetoclax-based treatment, including reported response rates, survival outcomes, and safety findings for SLS009 in combination with azacitidine and venetoclax. Preclinical results in T-cell prolymphocytic leukemia (T-PLL) and mechanistic studies in AML cell lines are also featured in conference-related releases.
In addition to clinical and scientific news, this page includes corporate updates such as participation in investor conferences, warrant exercise transactions, and quarterly financial results as reported in press releases referenced by Form 8-K filings. Investors and followers of SLS can use this page to review the sequence of material events, from R&D days and conference presentations to financing activities and operational updates, in one organized stream of company-specific news.
SELLAS Life Sciences Group (Nasdaq: SLS) announced a registered direct offering of approximately $16.2 million of its common stock at $7.00 per share, set to close around December 16, 2020. The company will sell 2,320,000 shares, expecting gross proceeds before fees and expenses. Maxim Group LLC acts as the exclusive lead placement agent for this offering. The shares are offered under a previously filed shelf registration statement and do not constitute an offer in jurisdictions where sales would be unlawful.
SELLAS Life Sciences Group (Nasdaq: SLS) announced positive results from its Phase 2 VADIS trial of nelipepimut-S (NPS) for ductal carcinoma in situ (DCIS) patients. The study showed a significant long-term immune response, with NPS+GM-CSF treatments increasing specific T-cell responses by up to 1,300% compared to control. The results, presented at the San Antonio Breast Cancer Symposium, suggest NPS may enhance immunity against HER2-expressing breast cancer. No serious adverse reactions were reported, supporting further development of NPS.
SELLAS Life Sciences Group has announced an Exclusive License Agreement with 3D Medicines, allowing the latter to develop and commercialize SELLAS' lead candidate, galinpepimut-S (GPS), in Greater China. SELLAS can earn up to $202 million, including a $7.5 million upfront fee and $8 million in near-term milestones, plus tiered royalties from sales. The deal enhances SELLAS' financial position and expands GPS's market reach, while 3D Medicines will handle development costs in China.
SELLAS Life Sciences Group has received approval for the Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia (AML) patients, allowing enrollment in France. The company strengthened its balance sheet with a $9.2 million financing, aimed at supporting ongoing clinical studies. Net loss for Q3 2020 was $4.5 million, a decrease from $11.5 million in Q3 2019. Cash and cash equivalents stood at approximately $8.2 million as of September 30, 2020. Challenges due to COVID-19 are affecting patient enrollment timelines.
SELLAS Life Sciences Group (SLS) announced the approval of its Investigational Medicinal Product Dossier (IMPD) by the French regulatory authority for its Phase 3 REGAL study of galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) patients who have achieved complete remission. This milestone allows for increased patient enrollment in France. Previous data from a Phase 2 study indicated a median overall survival of 21.0 months for GPS-treated patients, compared to 5.4 months with standard care. The REGAL study aims to evaluate overall survival and other key clinical endpoints.
SELLAS Life Sciences Group (SLS) recently strengthened its balance sheet with a $9.2 million private placement. The company is advancing its clinical programs for galinpepimut-S, including the Phase 3 REGAL study for AML, expected to yield multiple data readouts within 18 months. R&D expenses rose to $2.3 million in Q2 2020, compared to $1.4 million in Q2 2019, primarily due to REGAL study costs. The net loss for Q2 2020 was $4.4 million, or $0.66 per share, slightly increased from $4.1 million in Q2 2019. As of June 30, 2020, cash and cash equivalents stood at $3.3 million.
SELLAS Life Sciences Group (Nasdaq: SLS) announced on July 31, 2020, a private placement to raise approximately $9.2 million by offering up to 2,744,078 shares of common stock and accompanying warrants, priced at $3.335 per share. The transaction closing is expected on August 4, 2020, subject to customary conditions. Maxim Group LLC is the sole placement agent. The securities will not be registered under the Securities Act and are offered only to accredited investors. SELLAS is focused on innovative cancer immunotherapies, including its lead candidate, galinpepimut-S.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced its 2020 Annual Meeting of Stockholders will be held virtually on June 9, 2020, at 8:30 a.m. Eastern Time due to COVID-19. Stockholders of record by April 13, 2020, can vote and ask questions online starting at 8:15 a.m. Eastern Time. Participation requires a 15-digit control number and the meeting password: SLS2020. Beneficial owners must register in advance with Computershare by June 4, 2020. Stockholders can submit questions prior to the meeting or during the live webcast.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) reported its Q1 2020 financial results, emphasizing its commitment to ongoing clinical trials despite the COVID-19 pandemic. The company focuses on developing cancer immunotherapies with key progress in its galinpepimut-S (GPS) and nelipepimut-S (NPS) programs. As of March 31, 2020, cash and cash equivalents stood at $6.7 million. The net loss for the quarter was $4.2 million, with a loss per share of $0.66. Positive follow-up data for GPS indicated a median overall survival of 21 months for AML patients, compared to 5.4 months for standard care.